

RECEIVED

SEP 2 5 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Serial No.:

In re Application of: Gabriel Nunez et al. 10/014,268 269

Group No.:

Filed:

Examiner:

Entitled:

NOD2 Nucleic Acids and Proteins

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

RECEIVED

SEP 2 3 2003 **TECHNOLOGY CENTER R3700**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Dated: September 12, 2003

Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.


Applicant's believe no fee is required. This Information Disclosure Statement and PTO Form-1449 are being filed before the issuance of a first Office Action. If the Commissioner deems otherwise, the Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: September 12, 2003

Tanya A. Arenson

Registration No. 47,391

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 350 San Francisco, California 94105 608/218-6900



UM-06645 September 12, 2003

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of: Nunez et al.

Serial No.:

10/014,269

Group No.:

SFP 2 5 2003

Filed: Entitled: 10/26/01

Examiner:

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

NOD2 NUCLEIC ACIDS AND PROTEINS

Assistant Commissioner for Patents Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231, on **September 12, 2003**.

Bv:

Mary Ellen Waite

Sir or Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

- The following publications were cited in the International Search reports of copending PCT Applications WO 02/44426 and WO 02/36773:
- WO 01/72822;
- WO 99/64576;
- WO 99/40102;
- WO 01/90156;

RECEIVED

SEP 2 3 2003

TECHNOLOGY CENTER R3700

UM-06645 September 12, 2003

- Ogura et al., "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease," Nature Vol 411:603 [2001];
- Hugot et al., "Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease," Nature 411:6837 [2001];
- Inohara et al., "The NOD: A signaling module that regulates apoptosis and host defense against pathogens," Oncogene, 20:6473 [2001];
- Ogura et al., "Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappa B," J. Biol. Chem. 276:4812 [2001];
- Database EMBL, Human NOD2 protein mRNA, Database accession number AF178930;
- Database EMBL, June 7, 1999 "Sequencing of human chromosome 16,"
 Database accession no. AC007728;
- Database EMBL May 18, 1999 "Use of BAC end sequences from library RPCI 11 for sequence-ready map building," Database Accession No. AQ534686;
- Hugot et al., "Mapping of a susceptibility locus for Crohn's disease on chromosome 16," Nature 379:821 [1996];
- Miceli-Richard et al., "CARD15 mutations in Blau syndrome," Nature Genetics
 29:19 [2001]; and
- Inohara et al., "Nods: A family of cytosolic proteins that regulate the host response to pathogens," Curr. Opin. Microbiol. 5:76 [2002].

The following printed publications are referred to in the body of the specification:

- Aderem and Ulevitch, Nature, 406:785-787 [2000];
- Philpott et al., J. Immunol., 165:903-914 [2000];
- Leister and Katagiri, Plant J., 22:345-354 [2000];
- Hugot et al., Nature 379:821 [1996];

UM-06645 September 12, 2003

- Chou *et al.*, Cell, 94:171 [1998];
- Kobe and Deisenhofer, Curr. Opin. Struct Biol., 5:409-416 [1995];
- Zou et al., J. Bio. Chem. 274: 11549-11556 [1999];
- Schwandner *et al.*, J. Biol. Chem., 274: 17406-17409 [2000];
- Inohara et al., J. Biol. Chem. 274: 14560-14568 [1999];
- Li et al., Cell 91: 479-489 [1997];
- Snivasula et al., Mol. Cell 1: 949-957 [1998];
- Hu et al., J. Bio. Chem. 273: 33489-34494 [1998];
- Inohara et al., J. Biol. Chem. 273: 12296-12300 [1998];
- McCarthy et al., J. Bio. Chem. 273, 16968-16975 [1998];
- Parniske *et al.*, Cell 91: 821-832 [1997];
- Dixon et al., Proc. Natl. Acad. Sci. U. S. A. 97: 8807-8814 [2000];
- Aliprantis et al., Science, 285:736-739 [1999];
- Chow et al., J. Biol. Chem., 274:10689-10692 [2000];
- Bertin et al., J. Biol. Chem., 274:12955-12958;
- McCarthy et al., J. Biol. Chem., 273:16968-16975;
- Thome et al., Curr. Biol., 8:885-888 [1998];
- Inohara et al., J. biol. Chem., 275:27823-27831 [2000];
- Shimada *et al.*, Int. Immunol., 11:1357-1362 [1999];
- Huang et al., PNAS, 94:12829-12832 [1997];
- Medzhitov et al., Mol. Cell, 2:253-258 [1998];
- Hsu et al., Immunity, 4:387-396 [1996];
- Yamaoka et al., Cell 93: 1231-1240 [1998];
- Hu et al., EMBO J. 18: 3586-3595 [1999];
- Karin, J. Biol. Chem. 274: 27339-27342 [1999];
- Hofmann *et al.*, Trends Biochem. Sci. 22: 155-156 [1997];
- MacCorkle et al., Proc. Nat. Acad. Sci. U. S. A. 95: 3655-3660 [1998];

- Yang et al., Nature, 395:284-288 [1998];
- Zou et al., Cell, 90:405-413 [1997];
- Poltorak et al., Science, 282:2085 [1998];
- Takeuchi *et al.*, Immunity, 4:443 [1999];
- Rietschel et al., Curr Top. Microbiol. Immunol., 216:39-81 [1997];

Applicants have become aware of the following printed publications which may be material to the examination of this application:

- Cho et al., Inflammatory Bowl Diseases 3:186 [1997];
- Cho et al., Proc. Natl. Acad. Sci. 95:7502 [1998];
- Brant et al., Gastroenterology 115:1056 [1998];
- Cho et al., Hum. Mol. Gent. 9:1425 [2000];
- Cavanaugh et al., Ann. Hum. Gent. 62:291 [1998];
- Tysk et al., Gut 29:990 [1988].

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: September 12, 2003

Tanya A. Arenson Reg. No. 47, 391

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 350

San Francisco, California 94105

608 218-6900

FORM PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No.: UM-06645

Serial No.: 10/014,269

INFORMATION DISCHOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)

with next communication to applicant.

1 6 2003

Applicant: Gabriel Nunez et al.

Examiner Initials	011			HC DATENT DOG	•				Group Art Unit:		
	011			U.S. PATENT DOC	CUMENTS						
	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee · Cla		Class	Subclass	Filing Date			
		FC	DREIGN PATENTS C	R PUBLISHED FOR	REIGN PATENT APPI	LICATIONS		<u>-</u>			
		Document Number	Publication Date	Country / Patent Office		Class	Subclass	Translation Yes 1			
	1	WO 01/72822	4 October 01		РСТ		1				
	2	WO 99/64576	16 December 99		РСТ						
	3	WO 99/40102	12 August 99		РСТ						
	4	WO 01/90156	22 November 01		PCT			į			
		OTHER	DOCUMENTS (Inclu-	ding Author, Title, D	ate, Relevant Pages, Pl	lace of Publication)					
	5	Ogura et al., "A fra	ameshift mutation in N	OD2 associated with	susceptibility to Crohr	n's disease," Nature	Vol 411:603 [20	01]			
	6	Hugot et al., "Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease," Nature 411:6837 [2001]									
	7	Inohara et al., "The NOD: A signaling module that regulates apoptosis and host defense against pathogens," Oncogene, 20:6473 [2001]									
	8	Ogura et al., "Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappa B," J. Biol. Chem. 276:4812 [2001] Database EMBL, Human NOD2 protein mRNA, Database accession number AF178930									
4	9										
1	10	Database EMBL, June 7, 1999 "Sequencing of human chromosome 16," Database accession no. AC007728									
4	11	Database EMBL May 18, 1999 "Use of BAC end sequences from library RPCI-11 for sequence-ready map building," Database Accession No. AQ534686									
	12	Hugot et al., "Mapping of a susceptibility locus for Crohn's disease on chromosome 16," Nature 379:821 [1996]									
	13	Miceli-Richard et al., "CARD15 mutations in Blau syndrome," Nature Genetics 29:19 [2001]									
	14	Inohara et al., "Nods: A family of cytosolic proteins that regulate the host response to pathogens," Curr. Opin. Microbiol. 5:76 [2002]									
	15	Aderem and Ulevitch, Nature, 406:785-787 [2000]									
	16	Philpott et al., J. In	nmunol., 165:903-914	[2000]							
	17	Leister and Katagir	i, Plant J., 22:345-354	[2000]							
	18	Hugot et al., Natur	e 379:821 [1996]		3-15-12-1						
	19	Chou et al., Cell, 9	4:171 [1998]								
	20	Kobe and Deisenho	ofer, Curr. Opin. Struc	t Biol., 5:409-416 [19	995]	PE	<u> </u>				
	21	Zou et al., J. Bio. (Chem. 274: 11549-115	556 [1999]		, , , ,	-CEIV	ED			
	22	Schwandner et al.,	J. Biol. Chem., 274: 1	7406-17409 [2000]		St	P 2 3 200				
	23	Inohara et al., J. Bi	ol. Chem. 274: 14560	-14568 [1999]		TECHNOL	~ • ZUU	<u>J</u>	_		
	24	Li et al., Cell 91: 4	79-489 [1997]				CEIV P 2 3 200 OGY CENTER	R3700			
	25	Snivasula et al., Mol. Cell l: 949-957 [1998];									
	26	Hu et al., J. Bio. Chem. 273: 33489-34494 [1998]									
	27	Inohara et al., J. Bi	ol. Chem. 273: 12296	-12300 [1998]	, 		バビ				

TECH CENTER 1600/2900

SEP 1 6 2003 FORM PTO-1449 U.S. Department of Commerce Attorney Docket No.: UM-06645 Serial No.: 10/014,269 (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT Applicant: Gabriel Nunez et al. (Use Several Sheets If Necessary) Filing Date: 10/26/01 Group Art Unit: (37 CFR § 1.98(b)) OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication) 28 McCarthy et al., J. Bio. Chem. 273, 16968-16975 [1998] 29 Parniske et al., Cell 91: 821-832 [1997] 30 Dixon et al., Proc. Natl. Acad. Sci. U. S. A. 97: 8807-8814 [2000] 31 Aliprantis et al., Science, 285:736-739 [1999] 32 Chow et al., J. Biol. Chem., 274:10689-10692 [2000] 33 Bertin et al., J. Biol. Chem., 274:12955-12958 (1999) 34 Thome et al., Curr. Biol., 8:885-888 [1998] 35 Inohara et al., J. biol. Chem., 275:27823-27831 [2000] 36 Shimada et al., Int. Immunol., 11:1357-1362 [1999] 37 Huang et al., PNAS, 94:12829-12832 [1997] 38 Medzhitov et al., Mol. Cell, 2:253-258 [1998] 39 Hsu et al., Immunity, 4:387-396 [1996] 40 Yamaoka et al., Cell 93: 1231-1240 [1998] 41 Hu et al., EMBO J. 18: 3586-3595 [1999] 42 Karin, J. Biol. Chem. 274: 27339-27342 [1999] 43 Hofmann et al., Trends Biochem. Sci. 22: 155-156 [1997] 44 MacCorkle et al., Proc. Nat. Acad. Sci. U. S. A. 95: 3655-3660 [1998] 45 Yang et al., Nature, 395:284-288 [1998] 46 Zou et al., Cell, 90:405-413 [1997] 47 Poltorak et al., Science, 282:2085 [1998] 48 Takeuchi et al., Immunity, 4:443 [1999] 49 Rietschel et al., Curr Top. Microbiol. Immunol., 216:39-81 [1997] 50 Cho et al., Inflammatory Bowl Diseases 3:186 [1997] 51 Cho et al., Proc. Natl. Acad. Sci. 95:7502 [1998] 52 Brant et al., Gastroenterology 115:1056 [1998] 53 Cho et al., Hum. Mol. Gent. 9:1425 [2000] 54 Cavanaugh et al., Ann. Hum. Gent. 62:291 [1998] 55 Tysk et al., Gut 29:990 [1988] Examiner: Date Considered: **EXAMINER:**: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



SEP 2 3 2003 TECHNOLOGY CENTER R3700